Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Protein interaction network provides invaluable resource to identify targets for Huntington's disease

Researchers at the Buck Institute have identified and categorized thousands of protein interactions involving huntingtin, the protein responsible for Huntington's disease (HD). To use an analogy of a human social network, the identified proteins are like "friends" and "friends of friends" of the HD protein.

28 Feb 2014

Study provides novel insight into the impact of genes on Huntington's disease

A study led by researchers at Boston University School of Medicine provides novel insight into the impact that genes may have on Huntington's disease (HD). The study, published online in PLOS Genetics, identified specific small segments of RNA (called micro RNA or miRNA) encoded in DNA in the human genome that are highly expressed in HD.

27 Feb 2014

Researchers develop new compound that slows down progression of Huntington's Disease

Juliet Ross is suffering from Huntington's Disease, a rare neurological disorder that affects one in 10.000 people. Due to a genetic defect, her body produces a toxic protein that damages neurons in her brain.

26 Feb 2014

Cystinosis Research Foundation granted $2.15M in 2013 to researchers investigating cure for cystinosis

The Cystinosis Research Foundation awarded $2,153,048 in 2013 to researchers investigating better treatments and a cure for cystinosis, a rare metabolic and genetic disease that afflicts about 500 children and young adults in the United States and 2,000 worldwide.

19 Feb 2014

Omeros doses first patient in second Phase 2 clinical trial of OMS824

Omeros Corporation today announced dosing of the first patient in a second Phase 2 clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor being developed for the treatment of schizophrenia, Huntington's disease (HD) and other cognitive disorders. The Phase 2 trial will evaluate the tolerability, safety, pharmacokinetics and performance on a battery of tests in patients with symptomatic HD.

19 Feb 2014

RNA interference approach holds great promise for treating cancer and other diseases

Inspired by tiny particles that carry cholesterol through the body, MIT chemical engineers have designed nanoparticles that can deliver snippets of genetic material that turn off disease-causing genes.

12 Feb 2014

New approach for reducing levels of toxic protein fragments associated with Huntington's disease

An innovative therapeutic strategy for reducing the levels of toxic protein fragments associated with Huntington's disease uses a new approach called exon skipping to remove the disease-causing component of the essential protein, huntingtin.

11 Feb 2014

Omeros announces additional positive data from OMS824 Phase 1 program

Omeros Corporation today announced additional positive data from its Phase 1 program for OMS824, the lead compound in Omeros' phosphodiesterase 10 (PDE10) program. This clinical trial evaluated the extent to which OMS824 binds to PDE10, an enzyme expressed in the region of the brain that has been linked to a wide range of diseases that affect cognition. In the latest cohort enrolled in this trial, OMS824 achieved a high of approximately 70‑percent engagement at PDE10 without evidence of extrapyramidal symptoms (EPS).

11 Feb 2014

Researchers identify new subgroup of patients suffering from schizophrenia with motor disorders

Researchers led by Marta Barrachina, Institute of Neuropathology of the Bellvitge Biomedical Research Institute (IDIBELL) have identified a new subgroup of patients suffering from schizophrenia characterized by motor disorders.

29 Jan 2014

Omeros announces positive results from Phase 2a trial of OMS824 in patients with schizophrenia

Omeros Corporation today announced positive results from a Phase 2a clinical trial of OMS824, the company's phosphodiesterase 10 (PDE10) inhibitor, in which the drug was well tolerated and demonstrated comparable systemic pharmacokinetics when administered alone and concomitantly with approved antipsychotic agents in patients with schizophrenia. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including schizophrenia and Huntington's disease.

29 Jan 2014

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

Teva Pharmaceutical Industries Ltd. and Active Biotech (NASDAQ OMX NORDIC: ACTI) announced today that both companies remain committed to the NERVENTRA® (laquinimod) clinical development program for multiple sclerosis (MS) following the announcement of a negative opinion for the treatment of relapsing-remitting multiple sclerosis (RRMS) by the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA).

27 Jan 2014

Study reveals neurons in brain can combine signals of individual elements into behavioural sequence

When you learn how to play the piano, first you have to learn notes, scales and chords and only then will you be able to play a piece of music. The same principle applies to speech and to reading, where instead of scales you have to learn the alphabet and the rules of grammar.

26 Jan 2014

Biogen Idec, Sangamo BioSciences partner to develop therapeutics for hemoglobinopathies

Biogen Idec and Sangamo BioSciences, Inc. announced today an exclusive worldwide collaboration and license agreement focused on the development of therapeutics for hemoglobinopathies, inherited conditions that result from the abnormal structure or underproduction of hemoglobin.

9 Jan 2014

Research: New target for treating Huntington's and Parkinson's disease

Research from Western University (London, Canada) has revealed a possible new target for treating movement disorders such as Huntington's disease (HD) and Parkinson's disease. Stephen Ferguson, PhD, a scientist at Western's Robarts Research Institute, and Fabiola Ribeiro, PhD, of the Universidade Federal de Minas Gerais in Brazil found a definite improvement in motor behaviors in a HD mouse model when one of the major neurotransmitters in the brain, called Metabotropic Glutamate Receptor 5 (mGluR5) was deleted.

9 Jan 2014

Study raises hopes for new drugs to treat brain disorders associated with neurotransmitter imbalance

Although drugs have been developed that inhibit the imbalance of neurotransmitters in the brain - a condition which causes many brain disorders and nervous system diseases - the exact understanding of the mechanism by which these drugs work has not yet been fully understood.

8 Jan 2014

Omeros' OMS721 receives FDA orphan drug designation for prevention of TMAs

Omeros Corporation today announced that OMS721, the company's lead human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the key regulator of the lectin pathway of the immune system, has received orphan drug designation from the U.S. Food and Drug Administration for prevention of complement-mediated thrombotic microangiopathies.

18 Dec 2013

Otsuka, Lundbeck to develop investigational vaccine candidate for Alzheimer's disease

H. Lundbeck A/S (Lundbeck) and Otsuka Pharmaceutical Co., Ltd. (Otsuka) today announced that they will further expand their collaboration to include the development of Lu AF20513, an investigational vaccine candidate for Alzheimer's disease.

11 Dec 2013

Researchers develop new technique to cure human diseases caused by misfolded protein molecules

A team led by a longtime Oregon Health & Science University researcher has demonstrated in mice what could be a revolutionary new technique to cure a wide range of human diseases - from cystic fibrosis to cataracts to Alzheimer's disease - that are caused by "misfolded" protein molecules.

9 Dec 2013

Researchers take important step towards development of future drugs for brain diseases

A successful joint collaboration between researchers at the Hebrew university of Jerusalem and the startup company TyrNovo may lead to a potential treatment of brain diseases. The researchers found that TyrNovo's novel and unique compound, named NT219, selectively inhibits the process of aging in order to protect the brain from neurodegenerative diseases, without affecting lifespan. This is a first and important step towards the development of future drugs for the treatment of various neurodegenerative maladies.

4 Dec 2013

Protecting or boosting neurotrophins may slow progression of Huntington's disease

A drug that acts like a growth-promoting protein in the brain reduces degeneration and motor deficits associated with Huntington's disease in two mouse models of the disorder, according to a study appearing November 27 in the Journal of Neuroscience. The findings add to a growing body of evidence that protecting or boosting neurotrophins - the molecules that support the survival and function of nerve cells - may slow the progression of Huntington's disease and other neurodegenerative disorders.

27 Nov 2013

Huntington's Disease News and Research

Latest Huntington's Disease News and Research

Protein interaction network provides invaluable resource to identify targets for Huntington's disease

Study provides novel insight into the impact of genes on Huntington's disease

Researchers develop new compound that slows down progression of Huntington's Disease

Cystinosis Research Foundation granted $2.15M in 2013 to researchers investigating cure for cystinosis

Omeros doses first patient in second Phase 2 clinical trial of OMS824

RNA interference approach holds great promise for treating cancer and other diseases

New approach for reducing levels of toxic protein fragments associated with Huntington's disease

Omeros announces additional positive data from OMS824 Phase 1 program

Researchers identify new subgroup of patients suffering from schizophrenia with motor disorders

Omeros announces positive results from Phase 2a trial of OMS824 in patients with schizophrenia

Active Biotech, Teva remain committed to NERVENTRA clinical development program for multiple sclerosis

Study reveals neurons in brain can combine signals of individual elements into behavioural sequence

Biogen Idec, Sangamo BioSciences partner to develop therapeutics for hemoglobinopathies

Research: New target for treating Huntington's and Parkinson's disease

Study raises hopes for new drugs to treat brain disorders associated with neurotransmitter imbalance

Omeros' OMS721 receives FDA orphan drug designation for prevention of TMAs

Otsuka, Lundbeck to develop investigational vaccine candidate for Alzheimer's disease

Researchers develop new technique to cure human diseases caused by misfolded protein molecules

Researchers take important step towards development of future drugs for brain diseases

Protecting or boosting neurotrophins may slow progression of Huntington's disease

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Huntington's Disease News and Research

Latest Huntington's Disease News and Research

eBook: Advancing neurodegenerative research with iPSC-derived microglia models eBook

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in